



Second Quarter 2015 Financial Results Conference Call

August 4th, 2015

Namal Nawana, CEO and President
Jim Hinrichs, Chief Financial Officer
Juliet Cunningham, VP, Investor Relations



Forward-Looking Statements & Safe Harbor

This presentation contains information about future expectations, plans and prospects of Alere's management that constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Readers can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words and include statements regarding: future accelerated organic growth; the Company is positioned to meet organic growth targets; the timing of expected completion of divestitures; a recent acquisition will be immediately accretive and expect that it will result in greater market access and synergies over time; the expected impact of BBI disposition and USD acquisition on company's earnings; Company's intent with respect to divesting certain assets; the timing of the sale of the Company's interest in SPD; core business areas are accelerating growth; timing of expected 510(k) clearances; expected launch of reagents with laboratory and trade partners (and timing thereof); Company expected to capture increased molecular share in a rapidly expanding market; sales pipeline momentum is building for Alere i; Company believes Alere q will be requisite for certain diseases that requiring certain portable instruments; Company expects Alere q to build momentum in the second half of 2015 and beyond; future lateral flow respiratory tests (and the expected markets for and benefits of these products); future cost discipline; toxicology can return to growth by Q4; restructuring cost improvements will continue; operating expense discipline will continue to drive strong leverage to the bottom line through remainder of year; future financial operating results (including revenue and non-GAAP adjusted EPS from continued operations per diluted share for 2015); ability to remove costs over time; Company has opportunity to improve profitability throughout the P&L over the next 2 to 3 years; Company will experience growth in the second half of the year with new product launches, focused R&D and continued market expansion. Such forward-looking statements are estimates reflecting management's best judgment based upon current information and involve a number of risks and uncertainties. Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward-looking statements due to numerous factors, including without limitation, our ability to successfully and timely divest and integrate operations and to recognize the expected benefits of divestitures, restructurings and consolidations of our business activities; ability to execute on business plans to make acquisitions accretive, risks arising from FDA inspections and government subpoenas; our ability to successfully develop and commercialize products and services; the market acceptance of our products and services; the impact of healthcare reform legislation, as well as future reform initiatives; the content and timing of regulatory decisions and actions; the impact of changes in reimbursement policy and budgetary constraints, both in the United States and abroad; the effect of pending and future legal proceedings on our financial performance and the risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission, including our Form 10-K/A for the year ended December 31, 2014, as well as in our Quarterly Reports on Form 10-Q. Our Company undertakes no obligation to update forward-looking statements, including any financial guidance.

Projections, guidance and other forward-looking statements included in this presentation were issued on, and as of, August 4th, 2015. We are not reaffirming or confirming the continued validity of any of these projections, guidance or other statements as of future dates by inclusion in this presentation or by its continuing availability.



Second Quarter 2015 Highlights

- Net revenue of \$629.2 million; non-GAAP adjusted net revenue of \$629.4 million
- Organic revenue growth was 3.5 percent; excluding North America influenza sales, organic revenue growth was 3.3 percent
- \$0.17 income per diluted share available to common stockholders from continuing operations; non-GAAP adjusted income of \$0.54 per diluted share available to common stockholders from continuing operations



Q2 2015 Financial Summary


Quarter Ended June 30, 2015 (unaudited)

	GAAP	NON-GAAP*
\$s in millions, except EPS	Q2'15	Q2'15
Revenues	\$629.2	\$629.4
Gross Margins (\$)	\$292.6	\$307.1
Gross Margins (%)	46.5%	48.8%
Operating Expenses (\$)	\$200.7	\$191.8
Operating Expenses (%)	31.9%	30.5%
Income (Loss) from Continuing Operations Available to Common Stockholders (\$)	\$14.6	\$48.3
Diluted EPS	\$0.17	\$0.54

* Please visit <http://www.alere.com/ww/en/investor-relations/events.html> to view our Q2-2015 Press Financials which contain detailed reconciliations of the non-GAAP financial measures under GAAP.



Adjusted Organic Revenue Growth Trend




* Adjusted organic revenue growth is a non-GAAP financial measure that adjusts for impacts of acquisitions, divestitures, changes in foreign exchange translations, as well as adjustments related to acquired software license contracts




Q2 2015 Revenue Profile

BROAD & DIVERSE CUSTOMER BASE




Markets

STRONG RECURRING REVENUE



Products

GLOBAL PRESENCE



Geographies